A phase II study of first line chemotherapy by eribulin mesilate for HER2 negative recurrent breast cancer
Phase 2
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000007990
- Lead Sponsor
- Kobe Breast Cancer Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1) serious complication or past history: with symptomatic heart failure, liver cirrhosis, psychological disorder treated by antipsychotic drug, ischemic heart disease within 6 months, etc 2) active infection 3) peripheral neuropathy greater than Grade 3 4) male breast cancer 5) pregnant or nursing women, women who like be pregnant 6) with doctors decision for exclusion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method objective response rate
- Secondary Outcome Measures
Name Time Method progression free survival, over all survival, safety